申请人:Eisai Co., Ltd.
公开号:EP0686625A1
公开(公告)日:1995-12-13
An anthranilic acid derivative having a cGMP-PDE inhibitory activity and represented by general formula (I), or a pharmacologically acceptable salt thereof wherein R¹, R², R³ and R⁴ represent each independently hydrogen, halogen, hydroxy, optionally halogenated lower alkyl, optionally halogenated lower alkoxy, nitro, hydroxyalkyl, cyano, etc.; R⁵ and R⁶ represent each independently hydrogen, halogen hydroxy, cyano, optionally halogenated lower alkyl, optionally halogenated lower alkoxy, etc.; W represents -N= or -CH=; R⁷ and R⁸ represent each independently hydrogen, optionally halogenated lower alkyl, etc.; A represents hydrogen, optionally halogenated lower alkyl, etc.; Z represents hydroxy, optionally halogenated lower alkoxy, cyano, halogen, etc.; Y represents oxygen or sulfur; and n represents an integer of 0, 1 to 6.
一种具有 cGMP-PDE 抑制活性且由通式 (I) 表示的蒽酸衍生物或其药理学上可接受的盐 其中 R¹、R²、R³ 和 R⁴ 各自独立地代表氢、卤素、羟基、可选卤代低级烷基、可选卤代低级烷氧基、硝基、羟基烷基、氰基等;R⁵ 和 R⁶ 各自独立地代表氢、卤素羟基、氰基、可选卤代低级烷基、可选卤代低级烷氧基等。R⁵ 和 R⁶ 各自独立地代表氢、卤素羟基、氰基、任选卤代低 级烷基、任选卤代低级烷氧基等;W 代表 -N= 或 -CH=;R⁷ 和 R⁸ 各自独立地代表氢、任选卤代低 级烷基等。A 代表氢、任选卤化的低级烷基等;Z 代表羟基、任选卤化的低级烷氧基、氰基、卤素等;Y 代表氧或硫;n 代表 0、1 至 6 的整数。